Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice?

References

• Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 17(6), 1415–1422 (2011).
   PubMed Web of Science ®Google Scholar
• Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm. Bowel. Dis. 8(4), 244–250 (2002).
   PubMed Web of Science ®Google Scholar
• Miheller P, Kiss LS, Juhasz M, Mandel M, Lakatos PL. Recommendations for identifying Crohn’s disease patients with poor prognosis. Expert Rev Clin. Immunol. 9, 65–76 (2013).
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 138(2), 463–468; quiz e1–10 (2010).
   PubMed Web of Science ®Google Scholar
• Panaccione R, Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ. Evolving definitions of remission in Crohn's disease. Inflamm. Bowel. Dis. 19(8), 1645–1653 (2013).
   Google Scholar
• Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30(7), 983–989 (1989).
   PubMed Web of Science ®Google Scholar
• Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest. Endosc. 60(4), 505–512 (2004).
   PubMed Web of Science ®Google Scholar
• Daperno M, Van Assche G, Bulois P. Development of Crohn’s disease endoscopic score (CDES): a simple index to assess endoscopic severity of Crohn’s disease (abstract). Gastroenterology 122, A216 (2002).
   Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99(4), 956–963 (1990).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G et al. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut 25(6), 665–672 (1984).
   PubMed Web of Science ®Google Scholar
• Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn’s disease recurrence. Aliment. Pharmacol. Ther. 35(6), 625–33 (2012).
   PubMed Web of Science ®Google Scholar
• Chevaux JB, Vavricka SR, Rogler G et al. Mucosal healing with anti-TNF antibodies. Digestion. 86 (Suppl. 1), 16–22 (2012).
   Google Scholar
• Hébuterne X, Lémann M, Bouhnik Y et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut 62(2), 201–208 (2013).
   PubMed Web of Science ®Google Scholar
• Daperno M, Castiglione F, de Ridder LM et al. Scientific Committee of the European Crohn’s and Colitis Organization. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J. Crohns Colitis.. 5(5), 484–498 (2011).
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Geboes K, Peeters M et al. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114(2), 262–267 (1998).
   PubMed Web of Science ®Google Scholar
• Niv Y, Ilani S, Levi Z et al. Validation of the Capsule Endoscopy Crohn’s Disease Activity Index (CECDAI or Niv score): a multicenter prospective study. Endoscopy 44(1), 21–26 (2012).
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317(26), 1625–1629 (1987).
   PubMed Web of Science ®Google Scholar
• Baron JH, Connell AM, Lennard-Jones JE. Variation between Observers in Describing Mucosal Appearances in Proctocolitis. Br. Med. J. 1(5375), 89–92 (1964).
   PubMed Web of Science ®Google Scholar
• Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q. J. Med. 30, 393–407 (1961).
   PubMedGoogle Scholar
• Blackstone M. Inflammatory bowel disease Endoscopic Interpretation, ed. Raven Press, Blackstone MO, New York, 464–494 (1984).
   Google Scholar
• Osada T, Ohkusa T, Yokoyama T et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter- and intraobserver consistency. Inflamm. Bowel. Dis. 16(2), 192–197 (2010).
   PubMedGoogle Scholar
• D’Haens G, Sandborn WJ, Feagan BG et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 132(2), 763–86 (2007).
   PubMed Web of Science ®Google Scholar
• Thia KT, Loftus EV Jr, Pardi DS et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm. Bowel. Dis. 17(6), 1257–1264 (2011).
   Google Scholar
• Samuel S, Bruining DH, Loftus EV Jr et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 11(1), 49–54 e1 (2013).
   PubMed Web of Science ®Google Scholar
• Travis SP, Schnell D, Krzeski P et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 61(4), 535–542 (2012).
   PubMed Web of Science ®Google Scholar
• Geboes K, Riddell R, Ost A et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47(3), 404–409 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenberg L, Nanda KS, Zenlea T et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin. Gastroenterol. Hepatol. 11(8), 991–996 (2013).
   Google Scholar
• Modigliani R, Mary JY, Simon JF et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98(4), 811–8118 (1990).
   PubMed Web of Science ®Google Scholar
• Landi B, Anh TN, Cortot A et al. Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 102(5), 1647–1653 (1992).
   Google Scholar
• D’Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology 112(5), 1475–1481 (1997).
   PubMed Web of Science ®Google Scholar
• D’Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn’s (ileo-) colitis with azathioprine. Gastrointest. Endosc. 50(5), 667–671 (1999).
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Christidou A, Sfakianakis M et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn’s disease. Inflamm. Bowel. Dis. 15(3), 375–382 (2009).
   PubMed Web of Science ®Google Scholar
• Laharie D, Reffet A, Belleannée G et al. Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther. 33(6), 714–721 (2011).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126(2), 402–413 (2004).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med. 362(15), 1383–1395 (2010).
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371(9613), 660–667 (2008).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Sandborn WJ et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 142(5), 1102–1111 e2 (2012).
   PubMed Web of Science ®Google Scholar
• Hébuterne X, Lémann M, Bouhnik Y et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut 62(2), 201–208 (2013).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126(2), 402–413 (2004).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128(4), 856–861 (2005).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Reinisch W et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: special situations. J. Crohns Colitis 4(1), 63–101 (2010).
   PubMed Web of Science ®Google Scholar
• Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br. Med. J. 2(5321), 1708–1711 (1962).
   PubMed Web of Science ®Google Scholar
• Rachmilewitz, D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298(6666), 82–86 (1989).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm. Bowel Dis. 16(2), 338–346 (2010).
   PubMed Web of Science ®Google Scholar
• Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2006(2), CD000543 (2006).
   Google Scholar
• Orchard TR, van der Geest SA, Travis SP. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis – new light on a familiar question. Aliment. Pharmacol. Ther. 33(9), 1028–1035 (2011).
   Google Scholar
• Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing – ASCEND I and II combined analysis. Aliment. Pharmacol. Ther. 33(6), 672–678 (2011).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Regula J, Feagan BG et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 137(6), 1934–1943 (2009).
   Google Scholar
• Kamm MA, Sandborn WJ, Gassull M et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132, 66–75 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Kamm MA, Lichtenstein GR et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment. Pharmacol. Ther. 26(2), 205–215 (2007).
   Google Scholar
• Harris MS, Lichtenstein GR. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 33(9), 996–1009 (2011).
   Google Scholar
• Beattie RM, Nicholls SW, Domizio P, Williams CB, Walker-Smith JA. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 22(4), 373–379 (1996).
   Google Scholar
• Ardizzone S, Cassinotti A, Duca P et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin. Gastroenterol. Hepatol. 9(6), 483–489 (2011).
   PubMed Web of Science ®Google Scholar
• Gross V, Bar-Meir S, Lavy A et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment. Pharmacol. Ther. 23(2), 303–312 (2006).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment. Pharmacol. Ther. 30(2), 126–137 (2009).
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55(1), 47–53 (2006).
   PubMed Web of Science ®Google Scholar
• El-Matary W, Vandermeer B, Griffiths AM. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev, 2009(3), CD007560 (2009).
   Google Scholar
• Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J. Crohns Colitis 6(10), 991–1030 (2012).
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Naganuma M, Okamoto S et al. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J. Gastroenterol. 45(11), 1129–1137 (2010).
   Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2006(3), CD005112 (2006).
   Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60(6), 780–787 (2011).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2), 257–265, e1–3 (2012).
   PubMed Web of Science ®Google Scholar
• Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 32, 174–178 (1991).
   PubMed Web of Science ®Google Scholar
• Bitton A, Peppercorn MA, Antonioli DA et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120, 13–20 (2001).
   PubMed Web of Science ®Google Scholar
• Cellier C, Sahmoud T, Froguel E et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 35(2), 231–235 (1994).
   PubMed Web of Science ®Google Scholar
• Allez M, Lemann M, Bonnet J et al. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am. J. Gastroenterol. 97(4), 947–953 (2002).
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm. Bowel. Dis. 15(9), 1295–1301 (2009).
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 138(2), 463–468 (2010).
   PubMed Web of Science ®Google Scholar
• Louis E, Mary JY, Vernier-Massouille G et al. Groupe D’etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142(1), 63–70 (2012).
   PubMed Web of Science ®Google Scholar
• Lemann M, Mary JY, Colombel JF et al. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in longterm remission on azathioprine. Gastroenterology 128, 1812–1818 (2005).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141(4), 1194–1201 (2011).
   PubMed Web of Science ®Google Scholar
• Laharie D, Filippi J, Roblin X et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment. Pharmacol. Ther. 37(10), 998–1004 (2013).
   PubMed Web of Science ®Google Scholar
• Rutter MD, Saunders BP, Wilkinson KH et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53(12), 1813–1816 (2004).
   PubMed Web of Science ®Google Scholar
• Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126, 451–459 (2004).
   PubMed Web of Science ®Google Scholar
• Gupta RB, Harpaz N, Itzkowitz S et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133, 1099–105 (2007).
   PubMed Web of Science ®Google Scholar
• Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133(2), 412–4422 (2007).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, D’Haens G et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 145 (1): 149–157 (2013).
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Ferrante M, Magro F et al. Scientific Committee of the European Crohn’s and Colitis Organization. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J. Crohns Colitis 5(5), 477–483 (2011).
   PubMed Web of Science ®Google Scholar
• van der Valk ME, Mangen MJ, Leenders M et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 10.1136/gutjnl-2012-303376 (2012).
   Google Scholar